SCHEMBL2858744

SCHEMBL2858744

CCC(=O)c1ccc(-c2cc(NCc3ccc(CO)c(CO)c3)ccc2C)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 1/20 0.38
MAPT P10636 4/20 0.37
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PPARA Q07869 1/20 0.36
MAPK14 Q16539 1/20 0.35
FFAR1 O14842 2/20 0.35
FFAR4 Q5NUL3 2/20 0.35
NPC1 O15118 4/20 0.34
NR1H4 Q96RI1 1/20 0.34
RAB9A P51151 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GCG P01275 1/20 0.33
PPARG P37231 1/20 0.33
RARB P10826 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6472980 0.82 RAB9A (0.42) MAPTALDH1A1MEN1LMNAKMT2A
SCHEMBL2858749 0.82 MAPT (0.36) MAPTALDH1A1MEN1LMNAKMT2A
SCHEMBL2854700 0.80 VDR (0.61) VDRMAPTALDH1A1MEN1LMNA
SCHEMBL2877573 0.78 RAB9A (0.42) MAPTALDH1A1MEN1LMNAKMT2A
SCHEMBL2856205 0.75 ALDH1A1 (0.45) MAPTALDH1A1MEN1KMT2AMAPK14
SCHEMBL2858257 0.75 VDR (0.63) VDRALDH1A1PPARAL3MBTL1PPARG
SCHEMBL4884826 0.71 VDR (0.76) VDRMAPTLMNAPPARAFFAR1
SCHEMBL4888522 0.70 VDR (0.59) VDRPPARAFFAR1FFAR4NR1H4
SCHEMBL15450372 0.70 ALDH1A1 (0.50) MAPTALDH1A1MEN1KMT2APPARA
SCHEMBL2863416 0.69 VDR (0.58) VDRMAPTALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456160-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-01-20 EP disclosed
US-6924400-B2 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2005-08-02 US disclosed
EP-1456160-A2 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2004-09-15 EP disclosed
US-20030195259-A1 Triaromatic vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-16 US disclosed
WO-2003050067-A2 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195259-A1 Triaromatic vitamin D analogues CYP24A1, CYP2R1, VDR VDR 3/4885MAPT 3392/4885ALDH1A1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.